The Medicines Company - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The Medicines Company - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2015', provides an overview of the The Medicines Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of The Medicines Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of The Medicines Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of The Medicines Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the The Medicines Company's pipeline products

Reason To Buy 

- Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of The Medicines Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the The Medicines Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of The Medicines Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of The Medicines Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of The Medicines Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
The Medicines Company Snapshot 6
The Medicines Company Overview 6
Key Information 6
Key Facts 6
The Medicines Company - Research and Development Overview 7
Key Therapeutic Areas 7
The Medicines Company - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
The Medicines Company - Pipeline Products Glance 15
The Medicines Company - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
The Medicines Company - Clinical Stage Pipeline Products 17
Phase I Products/Combination Treatment Modalities 17
The Medicines Company - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
The Medicines Company - Drug Profiles 19
bivalirudin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
cangrelor 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
clevidipine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(meropenem+ RPX-7009) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(biapenem + RPX-7009) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ABP-700 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MDCO-216 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
oritavancin diphosphate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
carboetomidate 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
fibrinogen (recombinant) 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
methoxycarbonyl carboetomidate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
methoxycarbonyl etomidate 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
tigecycline 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
The Medicines Company - Pipeline Analysis 38
The Medicines Company - Pipeline Products by Target 38
The Medicines Company - Pipeline Products by Route of Administration 39
The Medicines Company - Pipeline Products by Molecule Type 40
The Medicines Company - Pipeline Products by Mechanism of Action 41
The Medicines Company - Recent Pipeline Updates 42
The Medicines Company - Dormant Projects 50
The Medicines Company - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 51
clopidogrel bisulfate 51
MDCO-2010 51
The Medicines Company - Company Statement 52
The Medicines Company - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

The Medicines Company, Key Information 6
The Medicines Company, Key Facts 6
The Medicines Company - Pipeline by Indication, 2015 9
The Medicines Company - Pipeline by Stage of Development, 2015 10
The Medicines Company - Monotherapy Products in Pipeline, 2015 11
The Medicines Company - Combination Treatment Modalities in Pipeline, 2015 12
The Medicines Company - Partnered Products in Pipeline, 2015 13
The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2015 14
The Medicines Company - Pre-Registration, 2015 15
The Medicines Company - Phase III, 2015 16
The Medicines Company - Phase I, 2015 17
The Medicines Company - Preclinical, 2015 18
The Medicines Company - Pipeline by Target, 2015 38
The Medicines Company - Pipeline by Route of Administration, 2015 39
The Medicines Company - Pipeline by Molecule Type, 2015 40
The Medicines Company - Pipeline Products by Mechanism of Action, 2015 41
The Medicines Company - Recent Pipeline Updates, 2015 42
The Medicines Company - Dormant Developmental Projects,2015 50
The Medicines Company - Discontinued Pipeline Products, 2015 51
The Medicines Company, Other Locations 54
The Medicines Company, Subsidiaries 55